Sensus Healthcare Settles Commercial Dispute with SkinCure Oncology
SRTS is trading near its 52-week low of $2.82 (11% above the low) on elevated volume (6.7× avg).
Summary
Sensus Healthcare announced the amicable resolution of a commercial dispute with SkinCure Oncology. This development removes a potential legal and operational overhang for the company, which recently reported a significant 59% year-over-year revenue decline in Q1 2026 and a default on a credit facility covenant in 2025. While specific financial terms were not disclosed, settling a commercial dispute reduces uncertainty and potential costs, which is particularly important for a small-cap company facing financial challenges. Traders will likely view this as a positive de-risking event, potentially stabilizing investor sentiment following recent negative earnings news.
At the time of this announcement, SRTS was trading at $3.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $2.82 to $5.92. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.